News Website

NICE approves first immunotherapy combination for endometrial cancer - NICE website

NICE approves first immunotherapy combination for endometrial cancer NICE website

Published: Aug. 5, 2025, 11 p.m.

Read Full Article

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma - PharmExec

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma PharmExec

Published: July 18, 2025, 10:08 a.m.

Read Full Article

Advanced Ovarian and Endometrial Cancers Respond to Combination Immunotherapy - Labroots

Advanced Ovarian and Endometrial Cancers Respond to Combination Immunotherapy Labroots

Published: July 14, 2025, 10 a.m.

Read Full Article

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) The Manila Times

Published: May 27, 2025, 12:47 p.m.

Read Full Article

Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - OncLive

Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer OncLive

Published: May 21, 2025, 2:09 p.m.

Read Full Article

Evaluation of Pyroptosis-Associated Genes in Endometrial Cancer Utilizing a 101-Combination Machine Learning Framework and Multi-Omics Data - Frontiers

Evaluation of Pyroptosis-Associated Genes in Endometrial Cancer Utilizing a 101-Combination Machine Learning Framework and Multi-Omics Data Frontiers

Published: April 25, 2025, 10:08 a.m.

Read Full Article

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer - OncLive

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer OncLive

Published: April 21, 2025, 1:17 p.m.

Read Full Article

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy The Malaysian …

Published: March 19, 2025, 10:53 p.m.

Read Full Article

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Weekly Voice

Published: March 19, 2025, 11:20 a.m.

Read Full Article

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy Yahoo Canada …

Published: March 19, 2025, 11 a.m.

Read Full Article

Latest Articles

NICE approves first immunotherapy combination for endometrial cancer - NICE website

Exploring the Promise of E7386 and Lenvatinib Combination Therapy in Endometrial Carcinoma - PharmExec

Advanced Ovarian and Endometrial Cancers Respond to Combination Immunotherapy - Labroots

Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times

Combinations Targeting PI3K/ AKT/mTOR and MAPK/ERK Pathways Are Under Study in Endometrial Cancer - OncLive

Evaluation of Pyroptosis-Associated Genes in Endometrial Cancer Utilizing a 101-Combination Machine Learning Framework and Multi-Omics Data - Frontiers

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer - OncLive

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - The Malaysian Reserve

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Weekly Voice

Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy - Yahoo Canada Finance

Subscribe to Our Newsletter